vs
Side-by-side financial comparison of BELDEN INC. (BDC) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $696.4M, roughly 1.1× BELDEN INC.). Insulet Corporation runs the higher net margin — 13.0% vs 7.3%, a 5.6% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 11.4%). Insulet Corporation produced more free cash flow last quarter ($48.2M vs $-63.1M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 7.3%).
Belden Inc. is an American, multinational, publicly traded company specializing in the design, manufacture, and distribution of end-to-end networking, security and connectivity products. The company serves the Industrial Automation Solutions, Smart Buildings and Broadband & 5G markets.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
BDC vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $696.4M | $783.7M |
| Net Profit | $51.0M | $101.6M |
| Gross Margin | 37.1% | 72.6% |
| Operating Margin | 11.2% | 18.7% |
| Net Margin | 7.3% | 13.0% |
| Revenue YoY | 11.4% | 31.2% |
| Net Profit YoY | -1.8% | 0.9% |
| EPS (diluted) | $1.30 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $696.4M | — | ||
| Q4 25 | $720.1M | $783.7M | ||
| Q3 25 | $698.2M | $706.3M | ||
| Q2 25 | $672.0M | $649.1M | ||
| Q1 25 | $624.9M | $569.0M | ||
| Q4 24 | $666.0M | $597.5M | ||
| Q3 24 | $654.9M | $543.9M | ||
| Q2 24 | $604.3M | $488.5M |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $67.9M | $101.6M | ||
| Q3 25 | $56.7M | $87.6M | ||
| Q2 25 | $61.0M | $22.5M | ||
| Q1 25 | $51.9M | $35.4M | ||
| Q4 24 | $58.4M | $100.7M | ||
| Q3 24 | $53.7M | $77.5M | ||
| Q2 24 | $49.0M | $188.6M |
| Q1 26 | 37.1% | — | ||
| Q4 25 | 36.6% | 72.6% | ||
| Q3 25 | 37.7% | 72.2% | ||
| Q2 25 | 38.5% | 69.7% | ||
| Q1 25 | 39.3% | 71.9% | ||
| Q4 24 | 37.5% | 72.1% | ||
| Q3 24 | 37.3% | 69.3% | ||
| Q2 24 | 37.5% | 67.7% |
| Q1 26 | 11.2% | — | ||
| Q4 25 | 12.2% | 18.7% | ||
| Q3 25 | 10.9% | 16.7% | ||
| Q2 25 | 11.8% | 18.7% | ||
| Q1 25 | 11.6% | 15.6% | ||
| Q4 24 | 10.4% | 18.3% | ||
| Q3 24 | 11.5% | 16.2% | ||
| Q2 24 | 11.4% | 11.2% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 9.4% | 13.0% | ||
| Q3 25 | 8.1% | 12.4% | ||
| Q2 25 | 9.1% | 3.5% | ||
| Q1 25 | 8.3% | 6.2% | ||
| Q4 24 | 8.8% | 16.9% | ||
| Q3 24 | 8.2% | 14.2% | ||
| Q2 24 | 8.1% | 38.6% |
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.70 | $1.42 | ||
| Q3 25 | $1.41 | $1.24 | ||
| Q2 25 | $1.53 | $0.32 | ||
| Q1 25 | $1.27 | $0.50 | ||
| Q4 24 | $1.41 | $1.38 | ||
| Q3 24 | $1.30 | $1.08 | ||
| Q2 24 | $1.19 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $272.2M | — |
| Total DebtLower is stronger | $1.3B | $930.8M |
| Stockholders' EquityBook value | $1.3B | $1.5B |
| Total Assets | — | $3.2B |
| Debt / EquityLower = less leverage | 0.98× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $272.2M | — | ||
| Q4 25 | $389.9M | — | ||
| Q3 25 | $314.3M | — | ||
| Q2 25 | $301.5M | — | ||
| Q1 25 | $259.0M | — | ||
| Q4 24 | $370.3M | — | ||
| Q3 24 | $323.0M | — | ||
| Q2 24 | $564.8M | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.2B | $998.4M |
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $3.2B | ||
| Q3 25 | $3.4B | $3.0B | ||
| Q2 25 | $3.4B | $3.5B | ||
| Q1 25 | $3.3B | $3.5B | ||
| Q4 24 | $3.3B | $3.1B | ||
| Q3 24 | $3.3B | $3.0B | ||
| Q2 24 | $3.5B | $2.9B |
| Q1 26 | 0.98× | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | $-63.1M | $48.2M |
| FCF MarginFCF / Revenue | -9.1% | 6.2% |
| Capex IntensityCapex / Revenue | 6.4% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $180.4M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $160.4M | $183.3M | ||
| Q3 25 | $105.0M | $125.7M | ||
| Q2 25 | $82.0M | $196.5M | ||
| Q1 25 | $7.4M | $63.8M | ||
| Q4 24 | $174.7M | $147.7M | ||
| Q3 24 | $91.7M | $98.5M | ||
| Q2 24 | $83.0M | $96.5M |
| Q1 26 | $-63.1M | — | ||
| Q4 25 | $121.3M | $48.2M | ||
| Q3 25 | $65.3M | $100.1M | ||
| Q2 25 | $56.9M | $177.9M | ||
| Q1 25 | $-24.8M | $51.5M | ||
| Q4 24 | $116.4M | $94.1M | ||
| Q3 24 | $67.2M | $71.8M | ||
| Q2 24 | $61.0M | $74.0M |
| Q1 26 | -9.1% | — | ||
| Q4 25 | 16.8% | 6.2% | ||
| Q3 25 | 9.4% | 14.2% | ||
| Q2 25 | 8.5% | 27.4% | ||
| Q1 25 | -4.0% | 9.1% | ||
| Q4 24 | 17.5% | 15.7% | ||
| Q3 24 | 10.3% | 13.2% | ||
| Q2 24 | 10.1% | 15.1% |
| Q1 26 | 6.4% | — | ||
| Q4 25 | 5.4% | 17.2% | ||
| Q3 25 | 5.7% | 3.6% | ||
| Q2 25 | 3.7% | 2.9% | ||
| Q1 25 | 5.2% | 2.2% | ||
| Q4 24 | 8.8% | 9.0% | ||
| Q3 24 | 3.7% | 4.9% | ||
| Q2 24 | 3.6% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 2.36× | 1.80× | ||
| Q3 25 | 1.85× | 1.43× | ||
| Q2 25 | 1.34× | 8.73× | ||
| Q1 25 | 0.14× | 1.80× | ||
| Q4 24 | 2.99× | 1.47× | ||
| Q3 24 | 1.71× | 1.27× | ||
| Q2 24 | 1.69× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDC
Segment breakdown not available.
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
